MBP Stock Overview
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Protagenic Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.47 |
| 52 Week High | US$3.14 |
| 52 Week Low | US$1.18 |
| Beta | 0.20 |
| 1 Month Change | 0% |
| 3 Month Change | 254.96% |
| 1 Year Change | -52.83% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -80.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| MBP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | 1.7% |
| 1Y | -52.8% | -23.0% | 2.3% |
Return vs Industry: MBP underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: MBP underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| MBP volatility | |
|---|---|
| MBP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MBP's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine MBP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.protagenic.com |
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company’s lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Protagenic Therapeutics, Inc. Fundamentals Summary
| MBP fundamental statistics | |
|---|---|
| Market cap | €7.66m |
| Earnings (TTM) | -€2.67m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs MBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.91m |
| Earnings | -US$2.91m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.67 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 5.8% |
How did MBP perform over the long term?
See historical performance and comparison